Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens

<p>Traditional vaccine development strategies are costly and time-consuming which makes them unsuitable for clinical assessment of new vaccines in the context of infectious diseases outbreaks. Platform technologies provide substantial manufacturing advantages and have the potential to signific...

Fuld beskrivelse

Bibliografiske detaljer
Hovedforfatter:	Moreira Folegatti, P
Andre forfattere:	Gilbert, S
Format:	Thesis
Sprog:	English
Udgivet:	2021
Fag:	Vaccine Clinical Development

Lignende værker

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
af: Adam Berg, et al.
Udgivet: (2021-10-01)

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
af: Charlotte Davis, et al.
Udgivet: (2024-06-01)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
af: Zhang, C, et al.
Udgivet: (2023)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
af: Cheng Zhang, et al.
Udgivet: (2023-06-01)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
af: Natalie Gabrielle Marchevsky, et al.
Udgivet: (2022-07-01)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
af: Pedro M. Folegatti, et al.
Udgivet: (2019-05-01)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
af: Hannah R. Sharpe, et al.
Udgivet: (2022-03-01)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
af: Rujittika Mungmunpuntipantip, et al.
Udgivet: (2021-11-01)

Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
af: Marek Mikołajczyk, et al.
Udgivet: (2022-12-01)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
af: César López-Camacho, et al.
Udgivet: (2020-06-01)

Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S
af: Bas de Laat, et al.
Udgivet: (2022-07-01)

ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukin‐6
af: Loes H. Willems, et al.
Udgivet: (2021-12-01)

Effectiveness of the chAdOx1 nCoV-19 vaccine in preventing COVID-19 infection
af: Tarana Sarwat, et al.
Udgivet: (2022-01-01)

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
af: Salma Al Bahrani, et al.
Udgivet: (2021-09-01)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
af: Folegatti, P, et al.
Udgivet: (2019)

A rare case of bilateral optic neuritis post-Covishield (ChAdOx1-S [recombinant]) vaccination
af: Tanie Natung, et al.
Udgivet: (2023-01-01)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
af: Simone Barocci, et al.
Udgivet: (2022-03-01)

Neutralizing Antibody and T-Cell Responses against SARS-CoV-2 Wild-Type and Variants of Concern in Chronic Obstructive Pulmonary Disease Subjects after ChAdOx-1/ChAdOx-1 Homologous Vaccination: A Preliminary Study
af: Warawut Chaiwong, et al.
Udgivet: (2022-12-01)

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
af: Lea Krutzke, et al.
Udgivet: (2022-07-01)

IgA Vasculitis Following ChAdOx1 nCoV-19 Vaccination
af: Manabendra Basu, et al.
Udgivet: (2024-01-01)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
af: Tamara Garibashvili, et al.
Udgivet: (2022-06-01)

Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination
af: Jaeeun Yoo, et al.
Udgivet: (2023-10-01)

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
af: Edmund G.-T. Wee, et al.
Udgivet: (2024-08-01)

Vaccine‐induced immune thrombotic thrombocytopenia with ChAdOx1 nCoV‐19 is rare in Asia
af: Kochawan Boonyawat, et al.
Udgivet: (2022-01-01)

DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination
af: Gerardo Casucci, et al.
Udgivet: (2021-06-01)

ChAdOx1 nCoV-19 Vaccine Side Effects among Healthcare Workers in Trinidad and Tobago
af: Chavin D. Gopaul, et al.
Udgivet: (2022-03-01)

Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 Covid-19 Vaccination – A Case Report
af: Martin Koch, et al.
Udgivet: (2021-07-01)

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
af: Larissa Henze, et al.
Udgivet: (2023-01-01)

Sarcoidosis presenting as bilateral optic neuritis after ChAdOx1 nCoV-19 vaccination
af: Amarendra Kumar Shukla, et al.
Udgivet: (2022-06-01)

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
af: Wang-Huei Sheng, et al.
Udgivet: (2022-04-01)

Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis
af: Ting-Yun Lin, et al.
Udgivet: (2022-08-01)

AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy
af: Syed B. Ali, et al.
Udgivet: (2022-03-01)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
af: Hermosilla, E, et al.
Udgivet: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
af: Eduardo Hermosilla, et al.
Udgivet: (2022-03-01)

Antibody Detection in Healthcare Workers after Vaccination with Two Doses of the BNT162b2 or ChAdOx1 Vaccine
af: Kyoung Ho Roh, et al.
Udgivet: (2022-09-01)

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
af: Jer-Hwa Chang, et al.
Udgivet: (2022-02-01)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
af: Jinnam Kim, et al.
Udgivet: (2023-04-01)

Adult-onset Still's disease after ChAdOx1 nCoV-19 vaccine: a possible association
af: Laíssa Fiorotti Albertino, et al.
Udgivet: (2022-11-01)

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV
af: Tamsin Cargill, et al.
Udgivet: (2023-11-01)

New Onset of Giant Cell Arteritis following ChAdOx1-S (Vaxevria<sup>®</sup>) Vaccine Administration
af: Luca Lo Sardo, et al.
Udgivet: (2023-02-01)